BIOSeedin Winter Innovation Partnering Summit : pleins feux sur J.P.Morgan

Core Insights - The BIOSeedin Winter Innovation Partnering Summit was held on January 11, 2026, in San Francisco, focusing on the China Asset Showcase to promote international presentation of Chinese innovative drugs and facilitate licensing cooperation [1] Group 1: Event Overview - The summit attracted over 500 industry representatives from more than 10 countries and regions, including multinational corporations, pharmaceutical and biotechnology companies, and leading investment institutions [2] - More than 300 individual meetings and 18 special tours of innovative Chinese biotechs were organized, reflecting a dynamic atmosphere of enthusiastic exchanges and strong collaboration intentions [2] Group 2: Industry Discussions - Three cross-border roundtables were held, where seasoned business development professionals and industry leaders discussed oncology, cardio-renal and metabolic diseases, and autoimmune diseases [3] - Key topics included differentiated national therapies for high-incidence cancers reshaping Chinese R&D in oncology, AI-accelerated clinical trials in cardio-renal and metabolic diseases, and multidimensional priorities for Sino-foreign cooperation in autoimmune diseases [3] - The 18 Chinese biotechs showcased high-quality assets in cutting-edge areas such as bispecific antibodies, ADCs, and molecular glues, aligning with industry hotspots and demonstrating successful R&D achievements in niche sectors [3] Group 3: Future Directions - The summit facilitated the gathering of global cutting-edge information, activated inter-regional and inter-sectoral cooperation, and created a professional bridge for the internationalization of Chinese innovative drugs [4] - BIOSeedin plans to leverage the value of its platform, organize high-quality industry events, and collaborate with global partners to explore investment opportunities and jointly shape the future of biopharmaceutical innovation [4]